Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab in Pediatric Generalized Myasthenia Gravis
2022-502539-21-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of nipocalimab in myasthenia gravis (MG), sponsored by Janssen Pharmaceutical. Planned start Jul 2023; status: authorised.
02
Drugs
nipocalimab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2022-502539-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502539-21-00.